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Background: Trypanosoma cruzi has been divided into Discrete Typing Units I and non-I (II-VI). T. cruzi I is
predominant in Mexico and Central America, while non-I is predominant in most of South America, including
Argentina. Little is known about congenital transmission of T. cruzi I. The specific aim of this study is to determine
the rate of congenital transmission of T. cruzi I compared to non-I.
Methods/design: We are conducting a prospective study to enroll at delivery, 10,000 women in Argentina, 7,500
women in Honduras, and 13,000 women in Mexico. We are measuring transmitted maternal T. cruzi antibodies by
performing two rapid tests in cord blood (Stat-Pak, Chembio, Medford, New York, and Trypanosoma Detect, InBios,
Seattle, Washington). If at least one of the results is positive, we are identifying infants who are congenitally
infected by performing parasitological examinations on cord blood and at 4–8 weeks, and serological follow-up at
10 months. Serological confirmation by ELISA (Wiener, Rosario, Argentina) is performed in cord and maternal blood,
and at 10 months. We also are performing T. cruzi standard PCR, real-time quantitative PCR and genotyping on
maternal venous blood and on cord blood, and serological examinations on siblings. Data are managed by a Data
Center in Montevideo, Uruguay. Data are entered online at the sites in an OpenClinica data management system,
and digital pictures of data forms are sent to the Data Center for quality control. Weekly reports allow for rapid
feedback to the sites.
Trial registration: Observational study with ClinicalTrials.gov Identifier NCT01787968
Keywords: Trypanosoma cruzi, Chagas disease, Congenital transmission, Latin AmericaBackground
Chagas’ disease, or American trypanosomiasis, is caused
by the protozoan parasite Trypanosoma cruzi. It is a
major cause of morbidity and mortality in the Americas,
and an estimated 9 million persons are currently infec-
ted [1]. Of particular concern is the fact that mothers
with Chagas’ disease can transmit T. cruzi to their
fetuses [2].
Mother-to-child transmission of T. cruzi has all the
characteristics required to be a public health priority, as
it is relatively frequent, severe, identifiable, and treatable
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stated.opportunity. Therefore, it is urgent to better understand
the epidemiology of mother-to-child transmission and to
develop effective prevention programs.
T. cruzi has been divided into Discrete Typing Units
(DTUs): T. cruzi I (TcI) and T. cruzi Non-TcI (II-VI).
In humans, TcI is predominant in Mexico and Central
America, while Non-TcI is predominant in most of South
America, including Argentina [4]. In recent studies from
Argentina, the risk of congenital transmission has been es-
timated to vary between 2.6% and 7.9% [5-8]. By contrast,
we know very little about the congenital transmission of
TcI. It has been suggested that congenital transmission of
T. cruzi is strain related [2,9], and there is an urgent need
to know if TcI transmits differently than Non-TcI. Our pri-
mary hypothesis is that congenital transmission rates are
different for TcI versus Non-TcI.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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predominant could differ in terms of risk factors for
transmitting T. cruzi to their offspring. Low maternal
age, low parity, HIV/AIDS, exposure to vectors and
high parasitic load have been reported as risk factors
for congenital T. cruzi infection [9-14]. Family clus-
tering has been observed in Argentina [15], sugges-
ting that some mothers might be predisposed to
transmit repeatedly.
There is limited information about the perinatal
outcomes of infected infants in low endemicity areas.
Congenital T. cruzi infection has been associated with
premature rupture of the membranes and preterm
births, in addition to neonatal complications [14]. Fur-
ther studies are needed to document the impact of
T. cruzi infection on perinatal outcomes.
The specific aims of this study are:
1. To determine the rate of congenital transmission of
TcI compared to Non-TcI;Figure 1 Study design.2. To compare the T. cruzi infected mothers’
characteristics and exposure to vectors in regions
where TcI is predominant and regions where
Non-TcI is predominant; and
3. To describe the birth outcomes of infected and
uninfected infants born to TcI and Non-TcI
seropositive women.
Methods/design
Overview
We are conducting a prospective study in Mexico,
Honduras, and Argentina. We are enrolling women at
delivery, collecting umbilical cord blood to measure
antibodies of maternal origin, and examining and follow-
ing up the infants of seropositive mothers and siblings
(Figure 1).
At the time of delivery and as soon as possible there-
after, umbilical cord venous blood is collected for all de-
liveries during the time periods selected for the study.
Written informed consent is obtained immediately after
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not ethically acceptable). If the woman declines to par-
ticipate, the cord blood sample is discarded, and no data
are recorded. If the woman accepts to participate, we are
measuring transmitted maternal T. cruzi antibodies by
performing two rapid tests in cord blood (Stat-Pak,
Chembio, Medford, New York, and Trypanosoma De-
tect, InBios, Seattle, Washington). If at least one of the
results is positive, we are identifying infants who are
congenitally infected by performing parasitological ex-
aminations on cord blood and at 4–8 weeks, and sero-
logical follow-up at 10 months. Serological confirmation
by recombinant ELISA (Wiener, Rosario, Argentina) is
performed in cord and maternal blood, and at 10
months. We will perform PCR followed by a qPCR and
genotyping on the blood of infected mothers and on the
umbilical cord blood.
Variables
The exposure to TcI will be defined by T. cruzi genotyp-
ing showing TcI on maternal blood and/or cord blood.
In the absence of successful T. cruzi genotyping on ma-
ternal or cord blood, births occurring in Mexico or
Honduras will be considered exposed to TcI.
The exposure to Non-TcI will be defined by T. cruzi
genotyping showing Non-TcI on maternal blood and/or
cord blood. In the absence of successful T. cruzi geno-
typing on maternal or cord blood, births occurring in
Argentina will be considered exposed to Non-TcI.
The exposure to both TcI and Non-TcI (co-infection)
will be defined by T. cruzi genotyping of both TcI and
Non-TcI on maternal blood and/or on cord blood, or
of TcI on maternal blood and Non-TcI on cord blood,
or of Non-TcI on maternal blood and TcI on cord blood.
The primary outcome (Specific Aim 1) will be the
congenital T. cruzi infection, which will be defined as
the presence of one or more of the following criteria:
– Presence of parasites in cord blood (direct
parasitological microscopic examination); and/or
– Presence of parasites in infant’s blood at 4–8 weeks
(direct parasitological microscopic examination);
and/or
– Persistence of T. cruzi-specific antibodies at 10
months, as measured by two tests.
A seropositive mother will have at least one positive
rapid test on cord blood and a positive ELISA on mater-
nal blood.
The mothers’ characteristics and exposure to vectors
variables (Specific Aim 2) that will be collected include:
– Maternal age;
– Parity (including current birth);– Infected sibling (yes/no) (siblings previously treated
for T. cruzi infection will be presumed as having
been infected);
– Maternal parasitic DNA amount;
– HIV serology (according to tests performed
routinely in each country);
– Presence of vectors in the household (Infestation)
(yes/no).
– Location in an area with risk of vectorial
transmission (yes/no)
The birth outcomes (Specific Aim 3) to be measured
are the following:
– Premature rupture of the membranes (PROM),
defined as rupture of membranes before admission
or before the onset of contractions, whatever the
timing of the rupture; [14]
– Gestational age (completed weeks), based on the
Last Menstrual Period (LMP) or a clinical estimate
(including ultrasound, if available) [16]. In the absence
of an ultrasound, the clinical estimate will be based on
the Capurro Score [17]. This score is the standard
method to evaluate gestational age by physical
examination of an infant at birth in Argentina and is
widely used in Latin America. The clinical estimate
will be used if the discrepancy between the LMP-
based estimate and the clinical estimate is greater
than 10 days; a preterm birth is <37 weeks;
– Birthweight (grams); a low birthweight baby weighs
<2,500 g;
– Head circumference (cm);
– Length (cm);
– Neonatal complications: We will use the definitions
of Torrico et al. [14] for the following variables, to
be registered at a physical examination of the infant
at not later than 24 hours of life:
Hepatomegaly (when ≥ 2 cm below the right costal
margin);
Splenomegaly (whatever the spleen size under the
left costal margin);
Anasarca (palpebral, genital, or leg edema alone will
not be considered);
Petechiae (whatever their localization);
Respiratory Distress Syndrome (RDS) will be
considered when at least one of the following signs
is present: tachypnea, throbbing of the ala nasi,
expiratory grunting, intercostal retraction, facial or
systemic cyanosis (peripheral cyanosis will not be
considered);
Neurological signs will be classified as present or
absent based on tone, level of alertness, Moro and
other primary neonatal reflexes, deep tendon
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(in search of mydriasis or miosis), bulging of
fontanelles, and convulsions.
Data about birthweight of siblings and breastfeeding
are collected by interviewing the mother at home using
the Honduras Demographic and Health Survey (DHS)
questions [18]. The DHS is a standardized survey ad-
ministered around the world, and it includes validated
questions and allows for international comparisons [19].
For each newborn and his/her siblings, we will also col-
lect data about blood transfusions, organ transplants,
and previous screening and treatment for T. cruzi.
Participating hospitals will be collecting data for all
women who consent to participate, using the format
of the Perinatal Information System of PAHO/WHO
already in use in Argentina, Honduras, and Mexico [20].
The variables collected include maternal age, reproduct-
ive history, HIV status, LMP, ultrasound examination,
PROM, mode of delivery, multiple births, Apgar score at
one and five minutes, birthweight, head circumference,
and length.
A live birth is a baby born with any sign of life, irre-
spective of gestational age [16]. A neonatal death is de-
fined as death before 28 complete days of life [16]. An
infant death will be defined as death before one year of
life [16].
Study population
Participating sites include: Hospital Materno Infantil and
Hospital General Valladolid, both in Yucatán, México;
Hospital Enrique Aguilar Cerrato, La Esperanza in
Intibucá, Honduras; Hospital Santa Bárbara in Santa
Bárbara, Honduras; and Instituto Maternidad Provincial
Nuestra Señora de las Mercedes in Tucumán, Argentina.
All consecutive live births occurring during the de-
fined study period will be included, irrespective of the
gestational age or the route of delivery (vaginal or
cesarean).
All subjects must meet all of the inclusion criteria to
participate in this study.
 Inclusion criteria: Women 18 years old or more,
informed consent, live birth.
All subjects meeting any of the exclusion criteria at
baseline will be excluded from study participation.
 Exclusion criteria: Women residing outside of the
follow-up area.
Follow-up
Newborns will be followed up at 4–8 weeks and
10 months. In each country, a dedicated team willperform home visits. The follow-up will be done within
the following geographical limits: in Mexico, the Yucatan
peninsula (i.e., the states of Yucatan, Campeche,
and Quintana Roo); in Honduras, the departments of
Intibucá and Santa Barbara; and in Argentina, the prov-
ince of Tucuman. A first home visit will take place at
4–8 weeks postpartum, when parasitological tests will be
performed again if the first parasitological examination
on cord blood was negative. Those infants with positive
tests will be considered infected and referred for treat-
ment. If the newborn has not been discharged from the
hospital at four weeks postpartum, the first follow-up
visit will be done in the hospital, and the first home visit
will be done within four weeks after discharge to collect
data on siblings. Those siblings who are not tested dur-
ing the first home visit will receive a second visit at 10
months postpartum.
The mothers of confirmed infected children and/or
mothers who are themselves confirmed as seropositive
will be informed and advised to contact their local health
provider. Repeated household visits will be performed
until follow-up at the health provider is confirmed, and
until the treatment of the infant is completed. Every
effort will be made to ensure that infants with congenital
T. cruzi infection identified at birth or at the 4-to-8-
week visit are treated by the health providers before the
10-month follow-up visit and that infants diagnosed at
the 10-month follow-up visit are also treated without
delay. Newborns and infected siblings will be treated
according to local standards, which include a course of
30 to 60 days of benznidazole or nifurtimox [2]. In
Honduras and Mexico, and in public hospitals in
Argentina, the treatment can only be obtained from the
Ministry of Health. We will provide each infected sub-
ject with a follow-up card, which will be stamped and
signed by the health provider at each follow-up visit and
when treatment is given. The mother will also be asked
to complete the card on a daily basis to indicate when
treatment has been given. We will perform household
visits every two weeks to confirm treatment. During
household visits, we will collect information from the
subjects’ cards and take digital pictures (with date and
time) of the cards. We will also register the number of
doses of benznidazole or nifurtimox made available to
the subject and take digital pictures (with date and time)
of the drug supply available in the household.
Geographic data will be collected for vector risk ana-
lysis. Street addresses are often unreliable in the areas
where participating women live; thus, detailed informa-
tion will be collected at enrollment. During the first
home visit, considerable effort will be made to locate the
household, involving key informants if needed. Once
located, we will use handheld computers with GPS
to map the location of the household. We will use
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Centers for Disease Control and Prevention (CDC) [21].
The latitude and longitude of the main entrance are de-
termined after obtaining the appropriate GPS signal, and
additional characteristics of the household are noted.
The sampling procedures included in the CDC software
are not needed here, but the system allows us to
navigate back to the household for return visits. In
addition, these GPS coordinates will be entered into a
GIS database (ArcView Geographic Information Systems
[ArcGIS] software 9.3, Environmental Systems Research
Institute, Redlands, CA) to produce maps of the geo-
graphic distribution of seropositive cases. These maps
will be used to estimate vectorial exposure in the house-
holds from the seropositive cases.Entomological data
Entomological data will be obtained from two different
sources to estimate vectorial exposure in the households
from seropositive mothers. First, we will use vector dis-
tribution and house infestation data from the respective
vector surveillance and control programs in Argentina
and Honduras, which provide geocoded information and
maps on the presence of vectors of different species at
the village/locality level. For each household of a sero-
positive mother, we will thus determine if it is located in
a village with or without known house infestation by
triatomines using cumulated vector data from the past
five years. For the Yucatan Peninsula, Mexico, in the ab-
sence of vector control programs, we will use published
entomologic risk maps [22]. Based on these maps,
households located in villages with low or absent risk
will be classified as without house infestation, and
households from villages with medium or high risk will
be classified as with house infestation.
Second, we will use the community participation
method, which was successfully piloted in and previously
used in Argentina as well [23]. All of the households
from seropositive mothers will be included, correspond-
ing to an estimated 100 households in Mexico, 300 in
Honduras, and 200 in Argentina. During the first house-
hold visit, information on Chagas’ disease and triato-
mines will be provided, including photographs and the
display of dried specimens of the vector, to ensure that
study participants will recognize the vector. Participants
will then be instructed to collect any triatomines ob-
served inside (domestic) or outside (peri-domestic) of
their homes using a safe procedure and to place them
into separate labeled plastic vials or bags. Any insects
captured since the time of the initial visit will be gath-
ered during the second visit at 10 months. Triatomine
species will be identified by local entomologists from
vector control programs in Argentina and Honduras andby entomologist researchers in Mexico, using established
entomological keys [24,25].
Because vector control is well underway in Argentina
and Honduras, we expect house infestation by triato-
mines to be limited in these countries, while triatomine
collections in Mexico will be much more important.
Based on these collections, each household will be clas-
sified as infested or non-infested, and infested house-
holds will be considered at risk of vectorial transmission,
irrespective of the T. cruzi infection status of the bugs.
T. cruzi infection status in triatomines will not be deter-
mined at this stage, as it is highly unlikely that a sufficient
sample size may be reached to determine significant differ-
ences in infection rates and T. cruzi transmission risk
between households. However, all collected insects will be
stored in ethanol for subsequent analysis and PCR diag-
nostic of infection if needed [26,27].
Blood samples and laboratory evaluations
Immediately after the clamping and sectioning of the
umbilical cord, 20 ml of venous umbilical cord blood
will be collected from the placental side of the cord with
a needle and syringe and placed in EDTA (15 ml) and
heparinized (5 ml) tubes following an established proto-
col. After obtaining informed consent, rapid serological
tests will be performed on cord blood within the next
six hours. If both rapid serological tests are negative, the
mother will be excluded from the study and we will se-
lect a randomized sample of the umbilical cord blood
samples to be stored.
If one of the cord blood rapid serological tests is posi-
tive, parasitological examinations will be performed im-
mediately, and samples will be stored for further testing
(10 ml on EDTA will be stored for molecular testing and
5 ml for further serological testing). 15 ml of venous ma-
ternal blood will be collected in EDTA tubes from
mothers and also stored (10 ml for molecular testing
and 5 ml for further serological testing).
The samples to be stored for further molecular testing
will be immediately mixed with the same volume of
guanidine-HCl 6M, EDTA 0.1 M (pH 8), and kept at 4°C
until processed. This standard blood treatment contrib-
utes to the stabilization of the sample’s DNA content
and improves its long-term conservation as well as fa-
vors the parasitic DNA dispersion into the entire sample.
Blood samples for further serological tests will be stored
in part on filter paper kept at 4°C until use, and add-
itional plasma samples will be frozen at −20°C until use.
During the 4-to-8-week follow-up household visits,
2 ml of blood will be collected in heparinized tubes from
the infant by venipuncture, or 6 heparinized capillary
tubes will be collected by heel stick and transported to
the laboratory in mobile refrigerators for parasitological
examination within a maximum of six hours. In those
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to fill 6 capillary tubes, collecting a blood sample large
enough to fill one capillary tube will be considered ac-
ceptable. Finger pricks will be used for siblings. A half
drop of blood (10 μl) will be collected from the finger
with a disposable pipette for the rapid serological test.
An additional 100 μl (5 drops) of blood will be stored on
filter paper for ELISA study.
During the 10-month household visit, 3 ml of blood
will be collected in EDTA tubes from the infant by
venipuncture and transported to the laboratory in mo-
bile refrigerators. Rapid tests will be performed, and
blood will be stored for further testing (filter paper at
4°C and plasma at −20°C). In those cases in which
venipuncture cannot be performed, we will collect blood
by heel prick or digital puncture in an Eppendorf
(or equivalent) EDTA tube to perform rapid tests and
further testing, and one filter paper for ELISA testing
will be considered an acceptable minimum.
The member of the follow up team who will perform
the venipunctures will be a certified phlebotomist. We
estimate that less than 1% of the samples will be un-
usable. Table 1 summarizes the blood samples to be
collected and analyzed.
We will use the Chagas Stat-Pak, a rapid immuno-
chromatographic screening test for detection of anti-T.
cruzi antibodies in whole blood [28,29]. We validated its
use on cord blood in the three countries in which weTable 1 Procedures with blood samples
Time of extraction Source Blood sample
Birth Umbilical cord 15 ml EDTA
Umbilical cord 5 ml heparinized
Before hospital
discharge*
Maternal, venous
in all (+) subjects
15 ml EDTA
Follow-up visit at 4–8
weeks after birth*
Infant, venous, or heel
stick
2 ml heparinized, 6 capil
or at least one capillary t
Siblings, finger prick 10 μl
100 μl
Follow-up visit at 10
months after birth*
Infant, venous or heel stick
or digital puncture
3 ml EDTA, or at least on
EDTA tube and one filter
*If at least one rapid test on cord blood is positive.are working [30]. A WHO comparative evaluation also
found 94% sensitivity for the Stat-Pak [31]. Other studies
have reported similar results in Bolivia [32-34], but a
lower sensitivity in Peru [33]. A half drop of blood
(10 μl) is collected with a disposable pipette and placed
on the rapid test cassette, and buffer is added. The pres-
ence of anti-T. cruzi antibodies in the sample produces a
pink/purple line (positive result) in the reactive area,
whereas no line appears in the absence of the antibodies
(negative result). A second pink/purple line in the control
area confirms that the reaction was completed and that
the test is validated. Reading the results in the appropriate
area of the device is performed by recording the absence
of any line as negative or a strong or weak line as positive.
All Stat-Pak results have to be read within 15 minutes.
Digital pictures (with date and time) are taken at the
15-minute mark to document the reading.
In addition to the Chagas Stat-Pak, we will use
Trypanosoma Detect (T. Detect) rapid immunochroma-
tographic screening tests (InBios, Seattle, Washington),
for detection of anti-T. cruzi antibodies in whole blood.
T. Detect has a 99% sensitivity and specificity compared
to consensus panel sera [35]. The test will be performed
according to the manufacturer’s instructions. Briefly,
20 μl of whole blood is added to the test strip. Three
drops of chase buffer solution are added into a test tube
or assay well where the test strip is placed. All T. Detect
results have to be read in 10 minutes. The test is positiveTests to perform Storage requirements
Stat-Pak. -
T. Detect,
ELISA*, Filter paper 4°C, Plasma
−20°C*
PCR* 10 ml Guanidine 4°C*
Parasitological
examination*
Max 6 hours at 4°C
Stat-Pak, -
T. Detect,
ELISA, Filter paper 4°C, Plasma
−20°C,
PCR 10 ml Guanidine 4°C
lary tubes (ideally),
ube
Parasitological
examination
Max 6 hours at 4°C
Stat-Pak -
ELISA Filter paper 4°C
e Eppendorf
paper
Stat-Pak, -
T. Detect,
ELISA Filter paper 4°C, Plasma
−20°C
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pictures are taken at the 10-minute mark to document
the reading.
Blood stored on filter paper and plasma samples will
be analyzed using a commercial ELISA prepared
with recombinant T. cruzi antigens (Chagatest ELISA
recombinant, version 3.0, Wiener Laboratories, Rosario,
Argentina), according to the manufacturer protocol.
Spots of blood will be punched from the filter paper,
eluted in the laboratory, and centrifuged and analyzed.
The use of filter paper for ELISA has been previously
described [36,37].
A confirmatory ELISA will be performed for all
10-month follow-up tests that are positive or in ques-
tion. The samples will be sent to Tulane University.
Serologic analysis will be performed according to the
manufacturer protocol using the FDA-cleared Hemagen
Chagas Kit (Hemagen Diagnostics, Inc., Columbia,
Maryland), a qualitative ELISA designed for the detection
of circulating antibodies to T. cruzi in serum and plasma.
Congenital infection with T. cruzi is sought for by dir-
ect microscopic examination of blood buffy coat col-
lected in six centrifuged microhematocrit heparinized
tubes as previously described [2,14,38,39]. In those cases
in which it is not possible to collect enough blood to fill
6 capillary tubes, collecting blood to fill at least one ca-
pillary tube will be considered acceptable. The detection
limit of such parasitological detection was estimated to
be 40 parasites/ml (p/ml) [38,39], which allowed the
detection of more than 90% of the congenital cases in
Bolivian endemic areas [40]. The number of positive
microhematocrit tubes containing parasites, as well as the
number of detected parasites per tube, allowed estimation
of parasitemia as either low (≥ 40 p/ml - < 150 p/ml),
medium (≥ 150 p/ml - ≤ 400 p/ml), or high (> 400 p/ml).
Positive parasitological examinations will be filmed when
possible. The films will be downloaded to the Chagas
study webpage and shared between the study sites.
We will perform molecular tests to estimate the para-
sitic DNA amount (PCR followed by a qPCR in positive
cases) and to identify the T. cruzi genotype (TcI and/or
Non-TcI) on the blood of infected mothers. We will also
perform PCR followed by genotyping on the umbilical
cord blood samples. An international consensus has
recognized direct parasitological examinations of cord or
neonatal blood collected in capillary tubes, as well as
serological investigations of infant blood at 10 months
of age, as the best tools for the biological diagnosis
of T. cruzi congenital infection, whereas PCR must still
be standardized and validated for such use [2]. Thus, the
research team is using blood parasitological examina-
tions and late serology to identify infected newborns.
PCR will not be used for diagnostic purposes, but it
will aid in verifying the presence of parasitic DNA insamples before they are quantified via qPCR or before
genotyping.
Data management
Data will be collected on paper case report forms (CRFs)
designed specifically for the study. Data will be collected
prospectively and kept confidential. The data will be col-
lected in the local language using hard copy forms, with
only the individual study identification number on each
form. No subject names will appear in the forms.
For each participating woman, a study number (alpha-
numeric, with check digit) will be assigned. A set of
labels with each number is designed to be pasted on the
CRFs of the mother and her children. Bar-coded labels
(Brady, Milwaukee, Wisconsin) will be pasted on each of
the blood samples. Names and other personal identifiers
are recorded in the inclusion form header, which are
stripped from the main body containing data. Each part
is identified with a study label number. The inclusion
form body will be sent to the local data center for data
entry. With this system, it is ensured that personal iden-
tifiers will not be taken from the hospital and will be
kept securely by the hospital coordinator.
Digital pictures (with date and time) of each CRF and
the rapid tests used for screening will be taken in each
country by the Field Research Coordinator and regularly
sent encrypted to the Data Center by uploading the in-
formation to a cloud-based system (Dropbox) [41]. This
system allows for a digital backup of all CRFs, as well as
a parallel second data entry of 10% of the forms at the
Data Center to detect systematic errors at data entry.
CRFs will also be entered on a daily basis in a secure
web data management system called OpenClinica, which
is open source software for clinical research studies
using distributed data entry. This software has been
adopted by the Department of Reproductive Health
and Research of the World Health Organization as
their data management systems, among other public re-
search groups. The system was adapted (forms and
rules) specifically for this study by the Clinical and
Epidemiological Research Montevideo Unit (UNICEM,
Montevideo, Uruguay), the study data center. The data
forms, checks, and rules were designed by the study re-
searchers in collaboration with the Data Center.
After the CRF has been entered into OpenClinica, it
will be placed into a folder labeled with the participant’s
unique subject ID. CRFs will be stored at the research
unit’s data entry center in locked cabinets. Only the
Country Data Manager has access to documents linking
patient personal information to study ID code numbers.
The Country Data Manager in each country will send
weekly reports to the Data Center regarding the screen-
ing, recruitment, consent, laboratory and follow-up pro-
cesses of the study. The Data Center will prepare weekly
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Data Manager and to the Principal Investigator of the
study.
Sample size
We are planning to study 600 mothers with T. cruzi
infection. The sample size will be achieved by recruiting
13,000 women in Mexico (estimated seroprevalence
of 1% in Merida and 0.4% in Valladolid), 7,500 in
Honduras (estimated seroprevalence of 4%), and 10,000
in Argentina (estimated seroprevalence of 2%). Based on
our pilot study, we estimate that 20% of deliveries will
be excluded because the age of the mother will be <18
or because consent is not obtained. In addition, we esti-
mate that 5% of the women will be ineligible because
they live outside of the follow-up area in Mexico (which
includes the entire Yucatan Peninsula) and that 10% will
live outside of the follow-up areas in Honduras and
Argentina (which include only each hospital’s depart-
ment or province).
We estimate that we will recruit 300 mothers with TcI
infection and 300 mothers with Non-TcI infection. We
will have more than 80% power to detect a difference of
1% transmission for TcI versus 5% for Non-TcI. We esti-
mate that the loss to follow-up will be lower than 10%.
Analysis plan
We will compute the rate of congenital transmission
among seropositive mothers according to the exposure
to TcI or Non-TcI with the corresponding confidence in-
tervals and compare them using binomial exact tests. A
seropositive mother will have at least one positive rapid
test on cord blood and a positive ELISA on maternal
blood. Cases with TcI/Non-TcI co-infection and with
maternal HIV/AIDS will be analyzed separately, and
transmission rates will be compared to the rest of the
population.
In a second step, we will repeat the analysis after ex-
cluding infants with negative parasitological examina-
tions and negative PCR on cord blood, and with a
history of transfusion and/or organ transplant, and/or
who are living in households exposed to the vector
(presence of vectors and/or location in an area at risk of
vector transmission). The resulting congenital transmis-
sion rate will be a more conservative estimate, which
will be less likely to be biased by non-congenital routes
of transmission. We will also stratify according to
breastfeeding (yes/no), another potential route of neo-
natal transmission.
We will adjust the comparison of TcI/Non-TcI trans-
mission rates for potential confounders:
– Maternal age at delivery (in five-year categories);
– Parity (primiparae/multiparae);– Presence of vectors in the household (yes/no);
– Maternal parasitic DNA amount;
– Mode of delivery (C. section vs. vaginal); and
– Infected sibling (yes/no) (siblings previously treated
for T. cruzi infection will be presumed as having
been infected).
Mantel-Haenszel chi-square tests will be used for
stratified analyses, which will take one categorical factor
into account at a time. A logistic regression will be also
performed and will include all potential confounders.
Adjusted odds ratios (OR) and confidence intervals will
be estimated.
We will describe birth outcomes (PROM, gestational
age, birthweight, head circumference, length, and neo-
natal complications) of infected and uninfected infants
by calculating proportions and confidence intervals for
categorical variables (including preterm birth and low
birthweight) and means and standard deviations for con-
tinuous ones. In a next step, we will stratify the analysis
by DTU (TcI/Non-TcI). We will compare intrauterine
growth restriction (IUGR) rates. A newborn will be clas-
sified as IUGR if its birthweight is below the tenth per-
centile of the sex-specific birthweight for gestational age
curves proposed by Williams et al. [42] for single and
multiple births. These growth curves are recommended
by the WHO as reference patterns for international
comparisons [43,44]. We will use the same reference for
the three countries to allow for comparison among sites.
In addition, we will also compute IUGR rates according
to a more recent U.S. reference curve [45] for single live
births to facilitate comparisons with the U.S. literature.
We will also analyze birthweight data of infected and
uninfected siblings by calculating proportions of low
birthweight and “very small babies” and confidence in-
tervals, mean birthweights, and standard deviations.
We will use STATA Version 8.0 [46] software for data
analysis.
Ethical aspects
The described protocol with informed consent and assent
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the Institutional Review Board of Tulane University and
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